HCMV activation of ERK-MAPK drives a multi-factorial response promoting the survival of infected myeloid progenitors by Kew, V et al.
Viral binding and entry provides the first trigger of a 
cell death response and thus how human cytomega-
lovirus (HCMV) evades this – particularly during la-
tent infection where a very limited pattern of gene ex-
pression is observed – is less well understood. It has 
been demonstrated that the activation of cellular sig-
nalling pathways upon virus binding promotes the sur-
vival of latently infected cells by the activation of cell 
encoded anti-apoptotic responses. In CD34+ cells, a 
major site of HCMV latency, ERK signalling is impor-
tant for survival and we now show that the activation 
of this pathway impacts on multiple aspects of cell 
death pathways. The data illustrate that HCMV infec-
tion triggers activation of pro-apoptotic Bak which is 
then countered through multiple ERK-dependent func-
tions. Specifically, ERK promotes ELK1 mediated 
transcription of the key survival molecule MCL-1, 
along with a concomitant decrease of the pro-apoptotic 
BIM and PUMA proteins. Finally, we show that the 
elimination of ELK-1 from CD34+ cells results in ele-
vated Bak activation in response to viral infection, re-
sulting in cell death. Taken together, these data begin 
to shed light on the poly-functional response elicited 
by HCMV via ERK-MAPK to promote cell survival. 
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promoting the survival of infected myeloid progenitors 
Introduction 
 
Amongst the first host responses activated upon viral 
infection are cell autonomous immune responses. 
These functions are ubiquitous to every cell type and 
are normally triggered by pattern recognition receptors 
which detect various components of the incoming 
pathogen (Bieniasz 2004; Everett & Chelbi-Alix 2007; 
Randow et al. 2013). One aspect of the cell autono-
mous immune response is the activation of apoptotic 
and cell death pathways, which will ultimately elimi-
nate both the pathogen and the infected cell (Clem et 
al. 1991; Everett & McFadden 1999; Levine et al. 
1993). During lytic infection, human cytomegalovirus 
(HCMV) counters this with an arsenal of virally en-
coded anti-apoptotic functions that counter stress sig-
nals induced by viral binding and, subsequently, 
throughout the course of viral replication (Brune 2010; 
Goldmacher et al. 1999; Guo et al. 2015; Reeves et al. 
2007; Skaletskaya et al. 2001; Stevenson et al. 2014; 
Terhune et al. 2007). However, a lack of expression of 
these functions in non-lytic infections raised the ques-
tion of how cell survival is achieved – particularly dur-
ing the initial phases of infection.  
 Current studies hypothesise that viral infection 
in cells non-permissive for lytic infection requires the 
generation of a pro-survival phenotype driven by 
virally induced up-regulation of key cellular anti-
apoptotic proteins (Chan et al. 2010; Peppenelli et al. 
2016; Reeves et al. 2012; Stevenson et al. 2014). This 
event relies on the regulation of a number of pro-
survival and pro-death signals via the modulation of 
cellular signalling pathways initiated upon virus bind-
ing and entry (Chan et al. 2010; Reeves et al. 2012). It 
is the outcome of these signalling events which, ulti-
mately, determines the fate of the cell during these 
very early stages of infection. Once latency is estab-
lished, there are additional mechanisms activated 
which would be consistent with the latent virus propa-
gating an anti-apoptotic state (Poole et al. 2011, 2015; 
Slobedman et al. 2004). 
 Apoptosis and cell death is an evolutionarily 
conserved process that is extensively regulated by Bcl-
2 homology domain 3 (BH3) proteins (Doerflinger et 
al. 2015; Horvitz 1999; Puthalakath & Strasser 2002). 
The precise mechanism of action still remains equivo-
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cal although it is clear that the BH3 proteins trigger the 
activation of key apoptosis effector proteins (e.g. Bak 
and Bax) which exert their pro-apoptotic function pre-
dominantly at mitochondrial membranes (Wei et al. 
2001; Westphal et al. 2014). A number of regulatory 
mechanisms have been suggested: The indirect activa-
tion model posits that Bax/Bak are required to be re-
tained in an inactive form via direct sequestration by 
anti-apoptotic BCL-2 family members (Willis et al. 
2005) and that BH3 proteins must engage with these to 
release the Bax/Bak to initiate apoptosis (Uren et al. 
2007; Willis et al. 2007).  The direct activation model 
hypothesises that BH3-only activators (e.g. PUMA and 
BIM) bind to Bak/Bax directly to activate them or, 
alternatively, other BH3 members (e.g. Bad) target 
BCL-2 members and inhibit their anti-apoptotic func-
tion through sequestration (Doerflinger et al. 2015; 
Erlacher et al. 2006; Kuwana et al. 2002; Villunger et 
al. 2003; Wei et al. 2000). The most recent evidence 
argues that these events are not mutually exclusive and 
that, instead, both mechanisms of regulation are likely 
to be active (Llambi et al. 2011; Westphal et al. 2014) 
although the strict delineation between activators and 
sensitisers in the BH3 family may not be entirely valid 
(Westphal et al. 2014).  
 Our own research interests have centred on the 
BCL-2-like protein myeloid cell leukaemia-1 (MCL-
1). Unlike other BCL-2 proteins the regulation of MCL
-1 is dynamic with a turnover of 30 minutes under cer-
tain experimental conditions (Adams & Cooper 2007; 
Warr & Shore 2008) and it is thus considered a highly 
responsive determinant of haematopoietic cell viability 
(Perciavalle & Opferman 2013) – the ablation of this 
protein from progenitor cells of the haematopoietic 
lineage being lethal (Opferman et al. 2005; Perciavalle 
& Opferman 2013). MCL-1 (along with BCL-XL) has 
been suggested to block Bak activity to exert an anti-
apoptotic function (Willis et al. 2005) and is regulated 
by both the PI3K and ERK-MAPK pathways (Huang 
et al. 2000; Mills et al. 2008). Pertinently, MCL-1 is 
also regulated by HCMV through activation of the 
ERK and PI3K pathways in a cell type specific manner 
(Chan et al. 2010; Reeves et al. 2012). Depletion of 
MCL-1 from monocytes or THP1 cells renders them 
unable to prevent virally induced cell death upon infec-
tion (Chan et al. 2010; Reeves et al. 2012). In CD34+ 
cells, HCMV survival is also associated with MCL-1 
(Reeves et al. 2012) although the absolute requirement 
for endogenous MCL-1 in normal CD34+ cells ren-
dered similar genetic analysis through MCL-1 deletion 
intractable. The inducible survival effect in CD34+ 
cells required virus binding and was likely dependent 
on the engagement of glycoprotein B with an unknown 
receptor. Furthermore, the survival effect induced was 
transient (Reeves et al. 2012) and thus did not appear 
to be propagated for as long as was observed in the 
monocyte model of infection (Chan et al. 2010). 
 ELK-1 is part of a 27 member superfamily of 
transcription factors that dictate a diverse range of 
processes including haematopoiesis, differentiation 
and survival, oncogenesis and inflammation 
(Sharrocks 2001). ELK-1 is a nuclear phosphoprotein 
that exhibits bimodal activity: redundant promoter 
binding via dimers with other Ets transcription factors 
and specific binding to a subset of genes through an 
interaction with serum response factor (SRF) 
(Odrowaz & Sharrocks 2012; Sharrocks 2001). 
Amongst these genes are MCL-1 and c-Fos, which, 
characteristically for this subset of genes, are dynami-
cally regulated (Boros et al. 2009; Treisman et al. 
1992). The activation of ELK-1 requires phosphoryla-
tion of serine residue 383 promoting the recruitment of 
transactivating co-factors to promoters in order to 
drive transcription (Boros et al. 2009; Gille et al. 1992, 
1995). Furthermore, ELK-1 mediated activation of 
MCL-1 gene expression has been shown to be impor-
tant for survival in a number of experimental models 
(Booy et al. 2011; Demir et al. 2011; Sun et al. 2013; 
Townsend et al. 1999) and likely contributes to the 
role of ELK-1 in cancer. 
 Herein we wanted to further explore the conse-
quences of HCMV infection on the development of an 
anti-apoptotic phenotype in CD34+ cells based on our 
previous studies of MCL-1 and ERK-MAPK signal-
ling. Here we show that the HCMV protection from 
cell death is concomitant with an inhibition of pro-
longed Bak activation in response to chemical and vi-
ral insult. Secondly, we show that the protective phe-
notype driven by virus induced ERK-MAPK signalling 
correlates with the down-regulation of pro-apoptotic 
BH3 proteins PUMA and BIM and, concomitantly, is 
dependent on the phosphorylation and thus activation 
of ELK-1 – a transcription factor important for MCL-1 
expression and cell survival. Importantly, knock down 
of ELK-1 expression is sufficient to abrogate the pro-
tective effect elicited by HCMV infection. Taken to-
gether, these data suggest that HCMV infection drives 
a survival phenotype by simultaneously up-regulating 
MCL-1 proteins levels and reducing the levels of an-
tagonistic interaction partners. We propose that the net 
effect tips the balance in favour of survival contribut-
ing to the successful establishment of latent infection. 
 
Materials and Methods 
 
Virus, cell lines, culture and reagents 
The Merlin strain of HCMV was purified from in-
fected human fibroblasts as previously described 
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(Compton 2000). Primary CD34+ haematopoietic cells 
(Lonza, Slough, UK) were resuscitated for 24 hours 
prior to any studies of cell viability in X-vivo-15 
(Biowhittaker, Lonza, Slough, UK) media supple-
mented with 10% human serum. For all subsequent 
studies, cells were switched into serum-free X-vivo 
media supplemented with 2mM L-Glutamine. For all 
infection experiments an MOI of 5 (based on titration 
in fibroblasts) was used. 
 Inhibition of the ERK-MAPK pathway was 
achieved using U0126 (final concentration 1uM; Cal-
biochem/Millipore, Darmstadt, Germany). The inhibi-
tor was added directly to the culture media with 0.1% 
DMSO used as the solvent control 1 hour prior to virus 
infection. 
 
Nucleic acid isolation, reverse transcription, PCR 
and Western Blot 
Ten micrograms of DNase I treated RNA isolated us-
ing RNAeasy spin columns was reverse transcribed 
using ImpromII RT kit (Promega, Madison, WI) or 
Quantitect Reverse Transcription Kit (Qiagen, Hilden, 
Germany). Chromatin Immunoprecipitations were per-
formed as previously described (Kew et al. 2014). 
Briefly, 106 cells were fixed and lysed and then sub-
jected to sonication to shear DNA into 200-500bp 
fragments. DNA was then incubated with anti-ELK1 
antibody (Cell Signaling, Danvers, MA; 1:100 dilu-
tion), anti-phospho ELK-1 antibody (Cell Signaling, 
Danvers, MA; 1:100 dilution) or an isotype matched 
control (mouse IgG1; SIGMA, St Louis, MO). DNA 
was rescued from the IP complexes and amplified with 
MCL-1 promoter specific primers.  
 Gene and promoter specific primers were then 
used to amplify target sequences by real time PCR us-
ing SYBR green amplification kit (Qiagen, Hilden, 
Germany).  MCL-1 (gene): 5’-TGC AGG TGT GTG 
CTG GAG TAG and 5’-GCT CTT GGC CAC TTG 
CTT TTC’, GAPDH: 5’-GAG TCA ACG GAT TTG 
GTC GT and 5’-TTG ATT TTG GAG GGA TTC 
TCG, 18S: 5’- GTA ACC CGT TGA ACC CCA and 
5’- CCA TCC AAT CGG TAG TAG CG, Bak: 5’-
GCC CAG GAC ACA GAG GAG GTT TTC and 5’-
AAA GTG GCC CAA CAG AAC CAC ACC, Bim: 
5’-CAC AAA CCC CAA GTC CTC CTT and 5’-TTC 
AGC CTG CCT CAT GGA A, Puma: 5’-ACG ACC 
TCA ACG CAC AGT ACG and 5’-TGG GTA AGG 
GCA GGA GTC C, UL138: 5’- GAG CTG TAC GGG 
GAG TAC GA and 5’- AGC TGC ACT GGG AAG 
ACA CT; MCL-1 (promoter): 5′-TAG GTG CCG 
TGC GCA ACC CT and 5′-ACT GGA AGG AAG 
CGG AAG TGA GAA (Booy et al. 2011). 
 For Western Blot, 105 cells were lysed in 
Laemmli buffer and subjected to SDS-PAGE electro-
phoresis. Following transfer, blots were incubated with 
anti-MCL-1 (Cell Signaling, Danvers, MA; 1:500), 
anti-ELK-1 or anti-phospho-ELK-1 (phosphor-serine 
383; Cell signaling, Danvers, MA; both 1:750), anti-
Bak (#06-536, Millipore, Darmstadt, Germany; 1:500), 
anti-PUMA (Santa Cruz, CA, 1:200) anti-actin 
(Abcam, Cambridge, UK; 1:1000) or anti-GAPDH 
(Abcam, Cambridge, UK; 1:2000) for 1 hour followed 
by detection with the appropriate HRP-conjugated sec-
ondary antibody. Specific bands were visualized by 
ECL detection (Amersham, Horsham, UK). 
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Figure 1. HCMV infection blocks cisplatin A mediated acti-
vation of Bak. (A) Western blot analysis of CD34+ cells 
either mock (M), HCMV infected (V) or cisplatin A treated 
(CspA) for Bak, MCL-1, BCL-XL, Bcl-2 or GAPDH ex-
pression 2 hours post-infection. (B) qRT-PCR analysis of 
RNA isolated from mock, HCMV infected or cisplatin A 
treated cells for Bak or MCL-1 expression 2 hours post-
infection. Changes in gene expression were identified using 
GAPDH and 2-ΔΔCT method. n=3 (C) CD34+ cells were 
mock or HCMV infected and then incubated with DMSO or 
cisplatin A 3 hours post-infection. Cells were then perme-
abilised and stained with an antibody that specifically recog-
nises an N terminal peptide exposed in activated Bak protein 
or with an isotype matched control. Fluorescent staining was 
achieved using a FITC-Goat anti-mouse antibody and then 
cells analysed by flow cytometry. 
siRNA knockdown 
CD34+ cells were transfected with Silencer® ELK-1 
siRNAs or Silencer® negative control (Thermofisher, 
Waltham, MA) using Viromer Green transfection re-
agent as described by the manufacturer (lipocalyx/
Cambridge Biosciences, UK). CD34+ cells were trans-
fected in bulk in X-vivo serum free media and then 
plated at the required density for downstream analyses 
at 48 hours post-transfection. Prior to plating, the viro-
mer:siRNA mix was removed from the cell culture 4 
hours post-transfection by pelleting the CD34+ cells at 
300g followed by resuspension in fresh X-vivo 15 me-
dia. 
 
Cell Death assay and Bak activation 
Induction of cell death was achieved using the chemo-
therapeutic drug cisplatin A (Rosenberg et al. 1965). 
Cisplatin A (25uM-250uM; SIGMA-Aldrich, St Louis, 
MO) or 0.1% DMSO (mock) control was added for 4 
hours to trigger the apoptotic pathway. Since the ef-
fects of cisplatin A induced cell death are not evident 
until at least 12-24 hours post treatment (Barry et al. 
1990) cell viability was performed 21 hours after cis-
platin A addition. To determine levels of cell death, 
cells were stained with a TUNEL detection kit (Roche, 
Basel, Switzerland) as described by the manufacturer 
and analysed for apoptotic cell death by immune-
fluorescent microscopy.  
 Alternatively, cell death was induced using the 
virus as a ligand through blockade of ERK-MAPK 
signaling (U0126; 1uM, Calbiochem) 1 hour prior to 
infection with HCMV. 0.1% DMSO was used as sol-
vent control. 
 Bak activation in CD34+ cells by flow cy-
tometry was measured as previously described 
(Griffiths et al. 1999). Briefly, 105 cells were incu-
bated with rabbit serum for 20 minutes and then with 
an anti-Bak antibody directed against the N terminal 
region (#06-536, Millipore, Darmstadt, Germany; 1:50 
dilution in PBS) or an isotype matched control for 15 
minutes at 4oC. Cells were washed, incubated with 
goat serum for 20 minutes and then incubated with a 
goat anti-rabbit FITC conjugated secondary antibody 
(1:100 dilution in PBS) for 15 minutes at 4oC. Un-
stained, isotype stained and Bak stained cells were 
then analysed by flow cytometry. 
 
Assays for latent infection 
CD34+ cells were infected with HCMV 48hrs post 
treatment with siRNAs in X-vivo-15 media for 3 
hours. Cells were pelleted, supernatant removed, 
washed in PBS and then re-suspended in fresh X-vivo 
media and cultured for 3 days. RNA was then isolated, 
converted to cDNA and amplified in a UL138 (viral 
gene) and 18S (cellular gene) specific PCR. Changes 
in gene expression were calculated using 2-ΔΔCT method 
(UL138 and 18S RNA). 
 
Results 
 
HCMV infection reduces the level of activated Bak 
in cisplatin A treated cells 
Our previous study had shown that HCMV infection 
could block the induction of CD34+ cell death in re-
sponse to the chemotherapeutic drug, cisplatin A 
(Reeves et al. 2012). Cisplatin A-induced degradation 
of survival molecules and the triggering of cell death 
are functionally entwined events (Yang et al. 2007). 
Here we show that in CD34+ cells, cisplatin A pro-
motes the degradation of pro-survival MCL-1, but not 
the related BCL-XL or Bcl-2 proteins (Figure 1A). As 
expected, HCMV infection promoted MCL-1 up-
regulation but, interestingly, no effect on BCL-2 or 
BCL-XL was again observed (Figure 1A). A key target 
of MCL-1 is Bak. However, no impact on the total lev-
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Figure 2. HCMV infection induces a transient activation of 
Bak which is not reversed when ERK responses are inhib-
ited. (A) CD34+ cells were infected with HCMV and then at 
times 0 to 3 hours post infection cells were permeabilised 
and stained for evidence of Bak activation by flow cytome-
try. (B-C) CD34+ cells were either pre-treated with an ERK 
inhibitor (B) or subjected to ELK1 or control siRNA knock-
down (C) and then either mock of HCMV infected. Cells 
were then permeabilised and stained for evidence of Bak 
activation by flow cytometry. 
els of Bak were observed whether treated with cis-
platin A or infected with HCMV (Figure 1A). Simi-
larly, no impact on the transcription of Bak was de-
tected at these early times post-infection (Figure 1B). 
In contrast, HCMV infection was a clear inducer of 
MCL-1 transcription (Figure 1B). We next investi-
gated the activation of Bak and although levels in the 
total protein did not change, evidence of increased ac-
tivation of Bak in response to cisplatin A was detected 
(Figure 1C). The specific activation of Bak can be de-
tected by flow cytometry utilising the conformational 
change that exposes Bak epitopes when active (i.e. pro
-apoptotic) Bak is released from the inactive complex 
it is normally sequestered in. As expected, resting 
CD34+ cells show very little evidence of Bak activa-
tion (Figure 1C) consistent with their viability status. 
In contrast, stimulation of CD34+ cells with cisplatin 
A resulted in a substantial increase in the level of acti-
vated Bak detectable in the cells (Figure 1C). Perti-
nently, minimal levels of active Bak were detectable in 
HCMV infected cells at 3hpi. Crucially, pre-infection 
with HCMV prior to cisplatin A treatment markedly 
reduced the detection of active Bak (Figure 1C) - con-
sistent with the protective phenotype of HCMV against 
cisplatin A. Taken together, these data suggested 
HCMV engendered a cellular phenotype that was di-
rectly antagonistic to cisplatin A induced cell death. 
 
HCMV activation of ERK-MAPK is necessary to 
prevent prolonged activation of Bak upon infection 
To investigate this further we first asked whether Bak 
activation occurred during viral infection – which 
would underpin the need to promote a cellular environ-
ment that antagonises Bak activation under normal 
infection conditions. Intriguingly, a time course analy-
sis revealed that Bak was clearly activated in infected 
cells at 1hpi and that, over time, the level of Bak acti-
vation was reversed by 3hpi (Figure 2A).  
 To explore this further we next exploited the 
knowledge that inhibition of survival pathways trig-
gered by HCMV promoted the death phenotype 
(Reeves et al. 2012). CD34+ cells were pre-incubated 
with ERK-MAPK inhibitor for 1 hour prior to infec-
tion (Figure 2B). Cells were then stained for Bak acti-
vation. As expected, there was little evidence of Bak 
activation at 3hpi in infected cells or cells treated with 
ERK inhibitor alone. However, the infection of cells 
with inhibited ERK-MAPK signalling resulted in a 
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Figure 3. HCMV infection promotes down-regulation of pro-
apoptotic proteins in an ERK dependent manner. (A,B) Western 
blot analysis of CD34+ cells either mock (M), HCMV infected 
(HCMV) or HCMV infected after 1 hour of pre-incubation with 
and ERK-MAPK inhibitor (ERK) for expression of PUMA (A) 
or BIM isoforms. (B) protein expression was performed at 2 
hours post-infection. GAPDH served as loading control. Densi-
tometry was used to measure relative levels of protein expression 
(C) qRT-PCR analysis of RNA isolated from mock or HCMV 
infected cells for PUMA, BIM or MCL-1 expression was per-
formed 2 hours post-infection. Changes in gene expression were 
identified using GAPDH and 2-ΔΔCT method, n=3. 
clear Bak activation phenotype (Figure 2B) and thus 
clearly pheno-copied the cisplatin effect. Taken to-
gether, the data show that HCMV infection activates 
Bak which it then reverses via the concomitant activa-
tion of ERK-MAPK signalling. 
 
HCMV modulates the activity of multiple Bak-
interacting functions in protected cells 
The activation of Bak in the mitochondrial membrane 
is elicited through a complicated interplay between 
effector and inhibitor mechanisms (Llambi et al. 
2011). Having already observed changes to the levels 
of the MCL-1 regulator we next asked whether any 
impact on activators of Bak were triggered by HCMV.  
Two key pro-apoptotic molecules reported to be up-
stream of Bak in this pathway are the pro-apoptotic 
PUMA and BIM BH3 proteins (Westphal et al. 2014). 
Western blot analyses indicated that basal levels of 
both PUMA and 2 of 3 BIM isoforms (BimEL and 
BimL) were detectable in uninfected cells. Further-
more, HCMV infected cells analysed at 1hpi suggested 
that a down-regulation of both PUMA and BimEL was 
evident. In contrast no changes in BimL were detected 
(Figure 3A, B). We also noted that the highly pro-
apoptotic isoform BimS (Marani et al. 2002) was not 
detectable nor was expression induced upon infection. 
The down-regulation of both PUMA and BIMEL prod-
ucts was specific to the protein as no effect on RNA 
levels was observed (Figure 3C). Finally, the reduction 
in both PUMA and BIMEL levels by HCMV was de-
pendent on ERK-MAPK activity (Figure 3A, B). 
 Thus HCMV activation of ERK-MAPK was 
promoting several related effects that would be condu-
cive for cell survival – BIM isoform and PUMA degra-
dation alongside an up-regulation of MCL-1 levels. 
MCL-1 protein levels within the cell are regulated by 
multiple processes. As well as increased transcription, 
MCL-1 is also regulated post-translationally with ERK 
hypothesised to promote a stabilising phosphorylation 
event of MCL-1 that antagonises degradation. Thus to 
investigate the potential contribution of transcription 
and translation of MCL-1 in response to HCMV, we 
reasoned we were required to understand the basis of 
HCMV induced up-regulation of MCL-1 mRNA ex-
pression. 
 Key elements responsible for the regulation of 
the MCL-1 promoter include binding sites for the ELK 
family of proteins (Booy et al. 2011). Western blot 
analysis of infected cells revealed that although 
HCMV binding did not increase the levels of ELK-1 in 
the cell, there was an apparent mobility shift which 
would be indicative of ELK-1 phosphorylation. This 
was confirmed using a phosphor-ELK1 specific anti-
body (Figure 4A). We next showed that the phos-
phorylation, and thus activation of ELK-1, was de-
pendent on ERK-MAPK signalling (Figure 4B). To 
link this clear activation of ELK-1 upon infection with 
MCL-1 expression we performed chromatin immuno-
precipitation analyses. These revealed that the ELK1 
protein was bound to the MCL-1 promoter in CD34+ 
cells irrespective of whether they were virally infected 
or not (Figure 4C). Although the data suggested that 
more ELK1 was bound in virally infected cells, it was 
the analysis of phosphorylated ELK1 bound to the 
MCL-1 promoter which exhibited the clearest pheno-
type. Here, viral infection promoted an increase in the 
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Figure 4. HCMV targets ELK1 for phosphorylation in an 
ERK dependent manner. (A) Western blot analysis of 
CD34+ cells, either mock (M) or HCMV infected (V) for 
ELK1 and ELK1 phosphorylation, 2 hours post-infection. 
Actin served as loading control. (B) Western blot analysis of 
CD34+ cells, either mock (M) or HCMV infected (HCMV) 
cells, with or without prior incubation with ERK-MAPK 
inhibitor (ERK) or DMSO control for 1 hour at 2 hours post- 
infection. Actin served as loading control. (C) Chromatin 
immuno-precipitation assays were performed on CD34+ 
cells with isotype (IgG), ELK1 or phosphor-ELK1 (ELK-
1p) antibodies. ChIPs were performed on CD34+ cells, 
HCMV infected CD34+ cells or the equivalent but with 
prior incubation with U0126 ERK inhibitor for 1 hour. Cells 
were analysed at 2 hours post infection, n=3. Students t-test 
was used to test for significance at p<0.05. 
detectable levels of pELK1 at the MCL-1 promoter 
and this event was significantly dependent on ERK 
signalling (Figure 4C). 
 To test whether ELK-1 was directly involved 
in the pro-survival phenotype we used siRNA knock-
down in CD34+ cells to address this. Delivery of ELK-
1 siRNAs significantly reduced ELK-1 protein present 
in the cell (Figure 5A) but did not result in any overt 
effects on cell viability over the short time frame of 
analysis (Figure 5C). Consistent with the ChIP data 
(Figure 4C), ELK-1 knockdown in the CD34+ cells 
dramatically impacted on the ability of HCMV to up-
regulate MCL-1 RNA expression (Figure 5B). To-
gether with the phenotypic impact on MCL-1 gene 
expression, there was a clear abrogation of the virally 
induced survival response (Figure 5C). Although the 
delivery of ELK-1 siRNAs alone was not deleterious 
to the cell, viral infection triggered a marked increase 
in cell death (Figure 5C) indicating that the elimination 
of ELK-1 from CD34+ cells renders them more sensi-
tive to HCMV induced cell death. 
 
ELK-1 knockout cells show elevated levels of Bak 
activation upon HCMV infection resulting in a less 
efficient establishment of latency 
Next, we revisited our studies of Bak activation using 
our ELK-1 knock down cells (Figure 6A). Unsurpris-
ingly, ELK-1 depletion from cells had little impact on 
levels of Bak activation. However, infection of ELK-1 
knock down cells again resulted in an increased detec-
tion of activated Bak (Figure 6A). Although the analy-
sis suggested that not all cells displayed evidence of 
activated Bak – which may reflect relative efficiency 
of siRNA knock down – the data clearly suggested that 
removal of ELK-1 from CD34+ cells promoted Bak 
activation in response to HCMV infection. 
 Finally, to assess if this was having any impact 
on the virus we assessed the ability of HCMV to estab-
lish latency (Figure 6B). Control or ELK-1 siRNA 
treated cells were infected with HCMV and analysed 3 
days post-infection for evidence of latent viral gene 
expression. It was evident that the failure to prevent 
virally induced cell death manifested with significantly 
reduced levels of UL138 expression, which would be 
consistent with a failure to establish a latent infection.  
 
Discussion 
 
In this study we have investigated the phenotype of the 
pro-survival environment elicited by infection of 
CD34+ cells with HCMV. This and previous studies 
provide accumulating evidence that HCMV is required 
to promote an anti-apoptotic environment through the 
activation of signalling pathways in non-permissive 
cells in order to ensure long term survival (Chan et al. 
2010; Peppenelli et al. 2016; Reeves et al. 2012; Ste-
venson et al. 2014). These events are likely critical for 
the pathogenesis and dissemination of virus in mono-
cytes and the establishment of latency in CD34+ cells. 
 The requirement for a pro-survival signalling 
cascade is necessitated by the evident induction of pro-
death responses which likely represent anti-viral re-
sponses to infection. This induction of pro-death re-
sponses is assumed to be due to the highly pro-
apoptotic phenotype associated with viral infection 
when the activity of the survival factors is impaired 
(Chan et al. 2010; Reeves et al. 2012). Thus HCMV 
cannot necessarily completely eliminate pro-death sig-
nalling but, instead, relies on the concomitant up-
regulation of survival factors to counter-balance this. It 
is of interest that a pan up-regulation of the anti-
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Figure 5. Depletion of ELK1 from CD34+ cells abrogates 
the HCMV survival response. (A) Western blot analysis of 
CD34+ cells 48 hours post-transfection with a control (Con), 
ELK1-specific (ELK) siRNA for ELK1 and GAPDH ex-
pression. (B) qRT-PCR analysis of RNA isolated from mock 
or HCMV infected cells 2 hours post-infection that have 
first been treated with either mock, control (Scr KD) or 
ELK1 (ELK KD) siRNAs. Changes in gene expression were 
identified using GAPDH and 2-ΔΔCT method, n=3. Students t
-test was used to test for significance at p<0.05. (C) CD34+ 
cells were either mock or HCMV infected and then, 3 hours 
post-infection, incubated with cisplatin A or DMSO control. 
Alternatively, CD34+ cells were transfected with control or 
ELK-1 specific siRNAs and then either mock or HCMV-
infected. In all experiments cell viability was measured 24 
hours post-infection. Graph is the average of 2 independent 
experiments analysed in triplicate. 
apoptotic machinery is not evident in the infected 
CD34+ cells. An analysis of 3 major players MCL-1, 
BCL-XL and BCL-2 revealed that only MCL-1 levels 
were affected by HCMV infection during the initial 
phases of latent infection in this cell type. However, 
we cannot dismiss a role for the other proteins com-
pletely, as the localisation or binding to target pro-
apoptotic proteins of these other BCL-2 family mem-
bers may be modified to augment the virally induced 
survival observed. Furthermore, our studies have really 
focussed on the role of MCL-1 as a transitory regulator 
during the very initial stages of infection. It is impor-
tant to note that data from studies performed in the 
monocyte model have shown that BCL-2 activity be-
comes increasingly important to maintain the viability 
of the infected cells (Collins-McMillen et al. 2015), 
suggesting that different molecules are required at dif-
ferent stages of viral infection. Consistent with this, 
reports in progenitor model systems have suggested 
that PEA-15 up-regulation via the activity of inter-
leukin-10 could play a role in long term latency in 
CD34+ cells (Poole et al. 2011, 2015; Slobedman et 
al. 2004). In this regard, the apparent targeting of the 
MCL-1 member of the BH3 family during the very 
early stages could be consistent with the central role 
that MCL-1 plays in the regulation of apoptosis in 
haematopoietic cells (Opferman et al. 2005) and also 
reflective of its more dynamic regulation in the cell 
(Adams & Cooper 2007). Unlike counterparts (e.g. Bcl
-2, Bcl-Xl), MCL-1 has a much shorter half-life 
(Adams & Cooper 2007). Ablation of MCL-1 results 
in spontaneous cell death in a number of cell lineages, 
indicating that, firstly, endogenous levels of other BCL
-2 proteins are not sufficient to compensate and sec-
ondly, it has a central role in haematopoietic cell sur-
vival (Dzhagalov et al. 2008; Opferman 2007; Opfer-
man et al. 2005). This exquisite sensitivity of primary 
cells to MCL-1 levels may also involve the complex 
interaction of MCL-1 with mitochondria (Huang & 
Yang-Yen 2010; Perciavalle et al. 2012). As well as a 
classical role in apoptosis, MCL-1 has also been 
shown to regulate ATP biogenesis (Perciavalle et al. 
2012) which we know, from studies of lytic HCMV 
infection, has a profound effect on the viability of in-
fected cells (Reeves et al. 2007). Whether the impact 
of MCL-1 on mitochondrial bioenergetics is important 
here is not clear but, given the relatively short lived 
nature of the protection in the experimental conditions, 
it is perhaps unlikely. It is more plausible to have a 
role either in the MCL-1 mediated protection of mono-
cytes where elevated MCL-1 expression persists for 72 
hours (Chan et al. 2010) or, it could possibly augment 
the function of beta 2.7 during lytic HCMV infection. 
 Cisplatin A mediated MCL-1 degradation is a 
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Figure 6. ELK-1 is required for the reversal of Bak activation and the establishment of HCMV latency. (A,B) CD34+ cells 
were subjected to ELK1 or control siRNA knockdown and then either mock of HCMV-infected. Cells were then either perme-
abilised and stained for evidence of Bak activation by flow cytometry at 3hpi (A) or analysed 3 days post infection for evi-
dence of viral latent gene expression (B). 
trigger for apoptosis (Yang et al. 2007) and thus tu-
mours exhibiting resistance to cisplatin A often display 
elevated levels of MCL-1 that is resistant to drug in-
duced degradation (Michels et al. 2014). It is hypothe-
sised that the degradation of MCL-1 exposes Bak to 
the activity of pro-apoptotic proteins like PUMA and 
BIM, ultimately resulting in Bak-mediated mitochon-
drial dysfunction (Letai et al. 2002). The precise nature 
of the inhibitory effect of MCL-1 on Bak is debated: 
MCL-1 could bind to Bak directly to block activation 
or could block activation by sequestering pro-apoptotic 
BH3 proteins like PUMA and BIM or, in fact, perform 
both functions (Erlacher et al. 2006, Letai et al. 2002; 
Marani et al. 2002; Willis & Adams 2005).  
 Another possibility is that although PUMA 
and BIM are pro-apototic proteins themselves and thus 
viral induced degradation is a mechanism to eliminate 
a direct activator, another consequence of the down-
regulation of these proteins could be contribute to in-
creasing the level of ‘free’ MCL-1 in the cell. Thus the 
up-regulation of MCL-1 and the down-regulation of a 
binding partner that sequesters it increase the likeli-
hood of an interaction with Bak. Additionally, very 
recent data suggests that the interaction of MCL-1 with 
Bak is induced under conditions that promote Bak oli-
gomerisation/activation (Dai et al. 2015). Thus, viral 
infection – an apparent trigger of Bak activation – pro-
motes a concomitant increase in MCL-1 levels which 
likely counters this. Indeed, it is interesting to note that 
when Bak activation was analysed at multiple points 
during the initial infection, we detected evidence of 
Bak activation at very early times which was quickly 
reversed. 
 Many of these observations were dependent on 
virally induced ERK-MAPK signalling. Viral induced 
activation of ERK-MAPK signalling and subsequent 
survival is a recurring theme suggesting that this path-
way is a common target (Dai et al. 2016; Liu & Cohen 
2013; Pleschka 2008; Pontes et al. 2015). The multi-
factorial response driven by ERK may also partially 
explain the observation that ELK-1 activity, whilst 
important, was never as detrimental as inhibition of 
upstream ERK signalling. Despite this, the induction 
of ELK-1 phophorylation was another virally induced 
response that was dependent on ERK-MAPK signal-
ling. Again, this had a pro-survival effect, whereby 
elimination of ELK-1 phosphorylation, and thus acti-
vation (Cruzalegui et al. 1999), either through inhibi-
tion of ERK-MAPK or via a siRNA depletion of ELK-
1 was deleterious, specifically upon virus infection. 
We note that evidence of ELK-1 binding to the MCL-1 
promoter prior to any stimulation was observed and, 
although viral infection provided evidence of increased 
occupancy of ELK-1, phosphorylation of ELK-1 was 
most important for MCL-1 transcription (Booy et al. 
2011; Cruzalegui et al. 1999). The observed occu-
pancy of ELK-1 in an unphosphorylated (presumably 
inactive) form at the promoter may suggest only a par-
tial involvement of ELK-1 in basal MCL-1 expression 
in the CD34+ cells but, instead, being important for 
dynamic responses to further stimuli. It would also be 
consistent with ELK-1 activation representing a 
mechanism for rapidly inducing MCL-1 expression 
(Booy et al. 2011; Vickers et al. 2004). This stimulus-
specific activity would explain the virally induced ef-
fects on MCL-1 and, also, the transient nature of the 
elevated MCL-1 expression (Reeves et al. 2012). The 
virus triggers a burst of ERK-MAPK activity upon 
entry promoting ELK-1 phosphorylation but once 
ERK signalling is down-regulated through normal 
feedback mechanisms (Fritsche-Guenther et al. 2011) 
coupled with a loss of the initial virus binding induced 
signal as the virus enters the cell, then MCL-1 expres-
sion returns to basal levels. The occupancy of inactive 
or even inhibitory (e.g. p50 homodimers) forms of 
transcription factors at promoters represents a mecha-
nism for rapid induction of gene expression and has 
been observed at multiple promoters (Altarejos & 
Montminy 2011; Baer et al. 1998; Herrera et al. 1989) 
including in our own studies of CREB and HCMV 
reactivation (Kew et al. 2014). Finally, although our 
analyses focused on the regulation of MCL-1 we can-
not preclude the possibility that ELK-1 activates multi-
ple responses (Boros et al. 2009) that contribute to sur-
vival upon viral infection. Indeed, pathogens often util-
ise central components in pathways, thus it would not 
be unsurprising to detect further ELK-1 controlled re-
sponses that are important. 
 Prescient to this study is that ERK-MAPK sig-
nalling under certain conditions can, for example, be 
pro-apoptotic (Cagnol & Chambard 2010; Cagnol et 
al. 2006;  Lu & Xu 2006) and thus in future studies it 
will be interesting to determine how HCMV directs the 
ERK response - possibly via the activation of con-
comitant pathways - to generate the pro-survival phe-
notype observed. Put simply, the kinase pathway that 
implements the final effector function (i.e. ERK-
MAPK) is not dictating the outcome alone - that deci-
sion is defined by the nature of the signalling milieu 
activating the ERK-MAPK module upstream and the 
signalling and molecular context that those pathways 
are being activated in. Thus an aim of future studies is 
to address the identity of the death signals that are acti-
vated by the host cell in response to viral infection. 
 What this study illustrates is that viruses are 
the master regulators of signalling cascades and path-
ways with an impressive ability to hijack, re-direct or 
partition them to enhance infection. Understanding 
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these events has greatly improved our understanding of 
cell biology and shed new light on the mechanisms 
that govern the activity of cellular functions required 
in key biological processes. Furthermore, it also illus-
trates how pleiotropic signalling pathways are modi-
fied to generate very specific outputs downstream. 
Greater understanding of these events and how they 
contribute to cell survival in the context of pathogen 
infection also has broader implications on our knowl-
edge regarding the decision a cell makes to live or die. 
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